info:eu-repo/semantics/article
Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy
Fecha
2014-11Registro en:
Preciado, María Victoria; Valva, Pamela; Escobar Gutierrez, Alejandro; Rahal, Paula; Ruiz Tovar, Karina; et al.; Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy; Baishideng Publishing Group; World Journal of Gastroenterology; 20; 43; 11-2014; 15992-16013
1007-9327
2219-2840
CONICET Digital
CONICET
Autor
Preciado, María Victoria
Valva, Pamela
Escobar Gutierrez, Alejandro
Rahal, Paula
Ruiz Tovar, Karina
Yamasaki, Lilian
Vazquez Chacon, Carlos
Martinez Guarneros, Armando
Carpio Pedroza, Juan Carlos
Fonseca Coronado, Salvador
Cruz Rivera, Mayra
Resumen
Hepatitis C virus (HCV) infection represents an important public health problem worldwide. Reduction of HCV morbidity and mortality is a current challenge owned to several viral and host factors. Virus molecular evolution plays an important role in HCV transmission, disease progression and therapy outcome. The high degree of genetic heterogeneity characteristic of HCV is a key element for the rapid adaptation of the intrahost viral population to different selection pressures (e.g., host immune responses and antiviral therapy). HCV molecular evolution is shaped by different mechanisms including a high mutation rate, genetic bottlenecks, genetic drift, recombination, temporal variations and compartmentalization. These evolutionary processes constantly rearrange the composition of the HCV intrahost population in a staging manner. Remarkable advances in the understanding of the molecular mechanism controlling HCV replication have facilitated the development of a plethora of direct-acting antiviral agents against HCV. As a result, superior sustained viral responses have been attained. The rapidly evolving field of anti-HCV therapy is expected to broad its landscape even further with newer, more potent antivirals, bringing us one step closer to the interferon-free era.